OverviewSuggest Edit

Abiomed is a company providing medical devices for circulatory support. It offers Impella, a small heart pump designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. Abiomed also provides clinical and product information, from professional resources to video training.

TypePublic
Founded1981
HQDanvers, MA, US
Websiteabiomed.com
Employee Ratings3.6
Overall CultureC-

Latest Updates

Employees (est.) (Mar 2019)1,371(+20%)
Job Openings149
Revenue (FY, 2020)$840.9 M(+10%)
Share Price (Jan 2022)$296.8(-4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Abiomed

Michael R Minogue

Michael R Minogue

Chairman, President and Chief Executive Officer
Marc A Began

Marc A Began

Vice President and General Counsel
William J Bolt

William J Bolt

Sr VP-Global Product Operations
Andrew J Greenfield

Andrew J Greenfield

Vice President and Chief Commercial Officer
Laxmi Peri

Laxmi Peri

Vice President of Engineering
Karen Mahoney

Karen Mahoney

Head of Global Human Resources
Show more

Abiomed Office Locations

Abiomed has offices in Danvers, Boston, Aachen and Chuo City
Danvers, MA, US (HQ)
22 Cherry Hill Dr
Boston, MA, US
53 State St
Aachen, DE
3 Neuenhofer Weg
Chuo City, JP
2-chōme-2-1 Nihonbashimuromachi
Show all (4)

Abiomed Financials and Metrics

Abiomed Revenue

Embed Graph
View revenue for all periods
Abiomed's revenue was reported to be $840.88 m in FY, 2020
USD

Revenue (Q3, 2021)

231.7m

Gross profit (Q3, 2021)

190.6m

Gross profit margin (Q3, 2021), %

82.3%

Net income (Q3, 2021)

61.9m

EBIT (Q3, 2021)

71.4m

Market capitalization (25-Jan-2022)

14.2b

Closing stock price (25-Jan-2022)

296.8

Cash (31-Dec-2020)

181.0m
Abiomed's current market capitalization is $14.2 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

445.3m593.7m769.4m840.9m

Revenue growth, %

35%33%30%

Cost of goods sold

70.6m98.6m129.6m151.3m

Gross profit

374.7m495.2m639.9m689.6m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

39.0m43.0m121.0m192.3m

Accounts Receivable

54.1m70.0m90.8m84.7m

Prepaid Expenses

8.0m11.8m13.7m18.0m

Inventories

34.9m50.2m80.9m90.1m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

52.1m112.2m259.0m203.0m

Depreciation and Amortization

6.2m11.0m14.1m20.4m

Inventories

(12.3m)(15.7m)(37.2m)(13.2m)

Accounts Payable

7.6m4.4m8.0m2.6m
USDQ1, 2017

Financial Leverage

1.1 x
Show all financial metrics

Abiomed Operating Metrics

FY, 2017FY, 2018FY, 2019

Facilities Owned

122

Products

588

Trademarks

12128

Trademarks Pending

5
Show all operating metrics

Abiomed Acquisitions / Subsidiaries

Company NameDateDeal Size
ECP Entwicklungsgesellschaft mbHJuly 01, 2014$13 m
Impella CardiosystemsApril 28, 2005
ABD Holding Company
ABIOMED Athlone Ltd
ABIOMED Australia Pte. Ltd
ABIOMED Europe
ABIOMED Japan KK
ABIOMED Limited
ABIOMED R&D
ABIOMED SARL
Show more

Abiomed Revenue Breakdown

Embed Graph

Abiomed revenue breakdown by business segment: 96.4% from Impella Product and 3.6% from Other

Abiomed revenue breakdown by geographic segment: 86.4% from US and 13.6% from International

Abiomed Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Abiomed Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Abiomed Online and Social Media Presence

Embed Graph

Abiomed Company Culture

  • Overall Culture

    C-

    65/100

  • CEO Rating

    D

    60/100

  • Compensation

    A-

    80/100

Learn more on Comparably

Abiomed News and Updates

$4.8 Billion Cardiac Assist Devices Global Market to 2027 - Players Include Abiomed, Berlin Heart and Getinge Group Among Others

Dublin, July 07, 2021 (GLOBE NEWSWIRE) -- The "Global Cardiac Assist Devices (CAD) Market - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Here’s Why Abiomed Stock Is Attractive After A 20% Drop

The stock price of Abiomed , a medical devices company best known for Impella, the world’s smallest heart pump, looks attractive at current levels of $280, despite it being up 2x from the levels of $132 it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19...

Abiomed Is Up 60% This Year, Can The Rally Continue?

The stock price of Abiomed, a medical devices company best known for Impella, the world’s smallest heart pump, is up roughly 60% since the beginning of this year, significantly outperforming the broader markets, with S&P 500 up a mere 7%. Despite the rally, at the current price of around $270...

FDA approves Abiomed heart pump to treat coronavirus patients

The Food and Drug Administration has approved the emergency use of Abiomed's Impella heart pump for Covid-19 patients with heart failure.

FDA approves emergency use of Abiomed heart pump for COVID-19 patients

Abiomed Inc said on Monday the U.S. Food and Drug Administration has granted emergency use authorization for its temporary invasive heart pump to help patients suffering from COVID-19 related right heart failure.

Abiomed gets emergency authorization to use heart pump in COVID-19 patients

Shares of Abiomed Inc. were down 0.04% in premarket trading on Monday after the company said it had received an emergency use authorization from the Food and Drug Administration for its Impella RP heart pump to be used in certain COVID-19 patients, including those with heart failure. The medical de…
Show more

Abiomed Frequently Asked Questions

  • When was Abiomed founded?

    Abiomed was founded in 1981.

  • Who are Abiomed key executives?

    Abiomed's key executives are Michael R Minogue, Marc A Began and William J Bolt.

  • How many employees does Abiomed have?

    Abiomed has 1,371 employees.

  • What is Abiomed revenue?

    Latest Abiomed annual revenue is $840.9 m.

  • What is Abiomed revenue per employee?

    Latest Abiomed revenue per employee is $613.3 k.

  • Who are Abiomed competitors?

    Competitors of Abiomed include Gerresheimer, Fresenius Kabi and Sopharma.

  • Where is Abiomed headquarters?

    Abiomed headquarters is located at 22 Cherry Hill Dr, Danvers.

  • Where are Abiomed offices?

    Abiomed has offices in Danvers, Boston, Aachen and Chuo City.

  • How many offices does Abiomed have?

    Abiomed has 4 offices.